Philip Astley-Sparke Sells 32,279 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) Director Philip Astley-Sparke sold 32,279 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $260,168.74. Following the transaction, the director now directly owns 1,405,071 shares of the company’s stock, valued at $11,324,872.26. The trade was a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Replimune Group Stock Down 4.7%

NASDAQ:REPL opened at $8.35 on Friday. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The company has a market cap of $643.08 million, a price-to-earnings ratio of -2.72 and a beta of 0.68. The stock has a fifty day simple moving average of $8.63 and a 200-day simple moving average of $11.21. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the firm earned ($0.25) EPS. Analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on REPL. HC Wainwright raised their target price on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $19.43.

Institutional Trading of Replimune Group

Several institutional investors and hedge funds have recently modified their holdings of REPL. Sterling Capital Management LLC grew its stake in Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after purchasing an additional 1,655 shares in the last quarter. US Bancorp DE grew its position in shares of Replimune Group by 582.6% during the 1st quarter. US Bancorp DE now owns 4,594 shares of the company’s stock worth $45,000 after buying an additional 3,921 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock worth $82,000 after buying an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd increased its stake in shares of Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after buying an additional 8,183 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Replimune Group by 106.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company’s stock valued at $111,000 after acquiring an additional 5,876 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.